

86. The composition of dendritic cell precursors according to claim 84 wherein the dendritic cell precursors are obtained from bone marrow.

BI CONT
87. The composition according to claim 83 wherein the antigen is produced by tumor cells.

88. The composition according to claim 83 wherein the antigen is an immunoglobulin.

Sub E2 89. The composition according to claim 83 wherein the antigen is a microorganism.

90. The composition according to claim 83 wherein the antigen is a virus.

91. The composition according to claim 83 wherein the antigen is a polypeptide.

92. The composition according to claim 83 wherein the antigen is a peptide.

93. The composition according to claim 83 wherein the antigen is a self-protein or an auto-antigen.

Sub E3 94. The composition according to claim 83 wherein the antigen is a mycobacteria tuberculosis bacteria.

95. The composition according to claim 94 wherein the mycobacteria tuberculosis bacteria is BCG.

Sub E4 96. A composition comprising an enriched population of human dendritic cells and a pharmaceutically acceptable carrier.

Sub
Ex
B1
cont
97. The composition according to claim 96 wherein the dendritic cells are antigen-activated.

98. A mixed culture of activated dendritic cells and T cells.

Sub
Ex
99. The pharmaceutical composition according to claim 97 wherein the antigen-activated dendritic cells express an amount of modified antigen to provide between about 1 to 100 micrograms of modified antigen per dose.

100. A pharmaceutical composition comprising a dendritic cell modified antigen wherein a substance to be modified is exposed to a culture of isolated dendritic cell precursors and whereby the substance is modified by the dendritic cells to produce modified antigen.

REMARKS

This application is a divisional of application Serial No. 08/458,230. For ease of examination, claims 1-81 have been cancelled, and new claims 82-101 have been added.

New claims 82-98 correspond to original claims 43-45, 54-57 and 64 which are drawn to dendritic cell compositions, and which are Invention II of the restriction requirement found in an office action dated November 11, 1993, in the grandparent application, Serial No.08/040, 677, filed on March 31, 1993.

Support for new claims 82-86, which are directed to compositions of isolated dendritic cell precursors isolated from blood or bone marrow, can be found in original claims 55-57.

Support for new claims 87-95, which are directed to the kinds of antigens suitable for use in this invention, can be found throughout the specification (*See*, e.g., page 33, lines 10-16), and in original claims 70-72.